英国围产期锂盐处方模式:基于初级保健队列研究
该研究基于英国初级保健数据库分析1995—2018年752 112次妊娠,评估围产期锂盐处方率及停药模式。孕期锂盐处方率低且持续下降,227例孕前处方者中仅15.4%全孕期持续用药,30.8%在孕中晚期停药;停药者更年轻、肥胖、患双相障碍、吸烟且产前咨询频繁。
要点
- 英国孕期锂盐处方率低,2018年仅1.03/10 000次妊娠。
- 孕前锂盐处方者中仅15.4%全孕期持续治疗。
- 30.8%在孕中晚期停药,需加强围产期随访。
核心结论
- 英国孕期锂盐处方不常见,但停药频繁,尤其在妊娠中晚期。
- 需主动的围产期精神卫生策略与密切临床监测,减少非意愿的孕早期暴露并保障母亲心理健康治疗的连续性。
研究设计与样本
- 基于人群的队列研究,使用英国临床实践研究数据链GOLD初级保健记录。
- 分析1995—2018年间752 112次妊娠,评估锂盐处方的患病率及停药、持续和剂量模式。
主要发现
- 每10 000次妊娠的锂盐处方患病率:孕前3.02(95%CI 2.64, 3.44),孕期1.89(95%CI 1.59, 2.23),产后2.81(95%CI 2.44, 3.21)。
- 孕期锂盐处方率在整个研究期间较低,2018年最近患病率为每10 000次妊娠1.03(95%CI 0.26, 4.11)。
- 337次围产期锂盐处方妊娠中,48.4%诊断为双相障碍。
- 227次孕前锂盐处方妊娠中,15.4%全孕期持续治疗,20.7%孕前停药,30.8%在孕中或孕晚期停药,33.0%为其他处方模式。
- 与持续治疗者相比,停药者更年轻、BMI≥30 kg/m2、诊断双相障碍、有吸烟史、孕前12个月内初级保健咨询>10次。
临床怎么用
- 围产期应主动评估锂盐治疗计划,对孕前处方者加强监测与随访。
- 关注年轻、肥胖、双相障碍、吸烟及频繁咨询的孕妇,识别停药高风险者。
- 平衡孕早期暴露风险与母亲心理健康治疗连续性,制定个体化围产期精神卫生策略。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although lithium has been used effectively as a medication to treat bipolar and major depressive disorders, there are limited data defining lithium use patterns during pregnancy. AIMS: To investigate trends and patterns of lithium prescribing in the perinatal period (before, during and after pregnancy) among pregnancies in the UK. METHOD: We conducted a population-based study using primary healthcare records from the Clinical Practice Research Datalink GOLD, analysing 752 112 pregnancies during the period 1995-2018. We assessed the prevalence and patterns of lithium prescriptions, including discontinuation, continuation and dosage. Maternal characteristics were defined for lithium non-users and users, and between those who continued and discontinued use. RESULTS: From 1995 to 2018, the prevalence of lithium prescribing per 10 000 pregnancies was 3.02 (95% CI: 2.64, 3.44) before pregnancy, 1.89 (95% CI: 1.59, 2.23) during pregnancy and 2.81 (95% CI: 2.44, 3.21) postpartum. Prescribing during pregnancy was low across the study period, with the most recent prevalence in 2018 of 1.03 (95% CI: 0.26, 4.11) per 10 000 pregnancies. Among 337 pregnancies with perinatal lithium prescribing, 48.4% involved a diagnosis of bipolar disorder. Of 227 pregnancies where lithium was prescribed preconception, 15.4% continued treatment throughout pregnancy; discontinuation occurred before pregnancy in 20.7%, and during second or third trimester in 30.8%; 33.0% followed other prescribing patterns. Women who discontinued lithium were more likely to be younger, have a body mass index ≥30 kg/m2, a diagnosis of bipolar disorder, a history of smoking and >10 primary care consultations in the 12 months preconception, compared with those who continued treatment. CONCLUSIONS: Lithium prescribing during pregnancy in the UK is uncommon and discontinuation is frequent, particularly in the later stages of pregnancy. These findings highlight the need for proactive perinatal mental healthcare strategies and close clinical monitoring, to reduce unintentional first-trimester exposure while ensuring continuity of care for maternal mental health.
引用
- Chauhan D, Madley-Dowd P, Hayes JF, et al. Lithium prescribing in the perinatal period: UK primary care cohort study. Br J Psychiatry. 2026. PMID: 41992689. doi:10.1192/bjp.2026.10632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。